This investigation encompasses all CAR-T therapies targeting BCMA and CD19 that have been approved for marketing, including six CAR-T therapies that have already been approved and marketed in the United States. These include Novartis's Kymriah (targeting CD19), Gilead's Yescarta (targeting CD19), Gilead's Tecartus (targeting CD19), Bristol Myers Squibb's Breyanzi (targeting CD19), Bristol Myers Squibb/Bluebird's Abecma (targeting BCMA), and Legend Biotech/Janssen's ciltacabtagene autoleucel (targeting BCMA).
